Japan Endometriosis Treatment Market Size, Share, Growth, and Industry Analysis, By Drug Type (Hormonal TherapyGonadotropin-Releasing Hormone (GnRH) Agonists Oral Contraceptives Progestins Danazol , Non-Hormonal Therapy NSAIDs Analgesics ), By Route of Administration (Oral , Injectables, Nasal , Others (e.g., implants, transdermal patches) ) and Forecast, 2026-2034

Japan Endometriosis Treatment Market Trends

Shift Toward Convenient, Long-Term Medical Management

Treatment patterns increasingly emphasize non-invasive and convenient pharmaceutical management before definitive surgery. Globally, endometriosis affects an estimated 10% of reproductive-age women, equivalent to approximately 190 million people, while Asian expert consensus has cited prevalence near 10% and Japanese self-reported evidence around 7%. These epidemiological levels support continued demand for therapies suitable for recurrent symptoms and prolonged disease management.

Oral GnRH-pathway therapies represent an important technology shift. Relugolix was developed as a once-daily oral GnRH receptor antagonist, and historical clinical development had evaluated the compound in more than 1,300 patients across indications. Digitalized regulatory processes are also advancing: PMDA electronic-data validation rule Version 6.0 became acceptable from April 2025, with its validation engine updated in April 2026, supporting increasingly standardized clinical submissions.

Japan Endometriosis Treatment Market Drivers

High Disease Burden and Need for Sustained Symptom Control

A substantial addressable patient population underpins treatment utilization. Published evidence places pelvic endometriosis prevalence at approximately 6%–10% among reproductive-age women and around 5%–21% among women experiencing pelvic pain. Global prevalence is estimated at 10%, or 190 million reproductive-age women, while Japanese evidence cited by Asia-Pacific experts indicates approximately 7% prevalence. Chronic pelvic pain, heavy menstrual bleeding and infertility-related disease burden increase requirements for repeated consultations, medical therapy and, for selected patients, surgery.

Japan Endometriosis Treatment Market Restraints

Diagnostic Complexity and Limitations of Existing Treatment

Endometriosis remains difficult to identify consistently because symptoms overlap with other gynecological and gastrointestinal conditions. Published prevalence estimates vary from approximately 5% to 21% among women with pelvic pain, while physician-diagnosed prevalence has been reported near 5%. Furthermore, the disease currently has no definitive cure; therapies principally control symptoms and longer-term consequences. These limitations can generate repeated treatment cycles and heterogeneous therapeutic responses.

Japan Endometriosis Treatment Market Opportunities

Expansion of Oral GnRH-Pathway Therapies

Innovation in orally administered hormonal therapies provides opportunities to reduce dependence on injections and invasive procedures. Relugolix has been developed as a once-daily oral GnRH receptor antagonist, with more than 1,300 patients historically evaluated across its development program. Takeda granted ASKA exclusive Japanese development and commercialization rights for relugolix in endometriosis, establishing a dedicated commercialization pathway within a country where published prevalence evidence has indicated approximately 7% among Japanese women.

Challenges in Japan Endometriosis Treatment Market

Balancing Long-Term Efficacy, Safety and Patient Persistence

Long-duration management requires clinicians to balance symptom suppression, tolerability, reproductive objectives and recurrence risks. Endometriosis affects about 10% or 190 million reproductive-age women globally, yet diagnostic estimates can range between 5% and 21% in symptomatic populations. This heterogeneity complicates standardized treatment pathways, while prolonged hormonal suppression and repeat interventions increase the importance of adherence, individualized prescribing and continuous monitoring.

Japan Endometriosis Treatment Market Segmentation

The market is segmented by drug type, route of administration, surgery type, distribution channel, and end-user. Based on supplied quantitative data, hormonal therapies represent approximately 56.0% of drug-type revenue in 2026, while oral products represent approximately 43.3% of route-based revenue.

By Drug Type

Hormonal therapy is the largest drug category, increasing from USD 35.54 million in 2025 to USD 40.28 million in 2026 and USD 109.69 million by 2034. The category records a 13.34% CAGR and includes GnRH agonists, oral contraceptives, progestins, and danazol.

Non-hormonal therapy, comprising NSAIDs and analgesics, rises from USD 28.10 million in 2025 to USD 31.63 million in 2026 and USD 81.50 million by 2034 at a 12.56% CAGR. Hormonal therapy is also the faster-growing of the two supplied drug categories at 13.34%.

By Route of Administration

Oral administration leads with USD 31.05 million in 2026, compared with USD 27.58 million in 2025, and is projected to reach USD 80.18 million by 2034 at a 12.59% CAGR. Injectables reach USD 48.27 million by 2034 at 12.51%, while nasal therapies reach USD 35.40 million at 13.34%.

Other administration routes, including implants and transdermal patches, are the fastest-growing category at 13.37% CAGR, advancing from USD 8.93 million in 2026 to USD 24.38 million in 2034. The supplied route total progresses from USD 71.78 million in 2026 to USD 188.23 million in 2034.

By Surgery Type

Surgical segmentation comprises conservative surgery, laparoscopy, laparotomy, and definitive surgery, principally hysterectomy with or without oophorectomy. No surgery-type revenue or CAGR values were supplied, preventing unsupported numerical allocation.

Medical management remains relevant before or alongside surgery, particularly given disease recurrence and fertility-preservation considerations. Consequently, no largest or fastest-growing surgical subsegment is numerically designated without source data.

By Distribution Channel

Distribution is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Prescription-based hormonal products and physician-directed therapies maintain the importance of regulated dispensing channels.

No channel-specific market values or CAGRs were supplied. Accordingly, hospital, retail, and online pharmacy dominance or forecast rates cannot be quantified without introducing unsupported estimates.

By End-User

End-users comprise hospitals and clinics, homecare, specialty centers, and others. Clinical facilities remain integral to diagnosis, prescription management, imaging, surgery, and follow-up, while homecare supports continued administration of suitable therapies.

No end-user revenue or CAGR data were supplied; therefore, numerical rankings between hospitals and clinics and homecare and specialty centers are not inferred.

Japan Endometriosis Treatment Market Counties Outlook

Japan is the sole geographic market covered by the supplied dataset. National drug-type revenue increases from USD 63.64 million in 2025 to USD 71.91 million in 2026 and USD 191.19 million by 2034, corresponding to 12.95% CAGR. Hormonal products contribute approximately 56.0% of 2026 drug-type revenue versus approximately 44.0% for non-hormonal therapies.

No prefectural or subnational split for Kanto, Kansai, Chubu, Kyushu, Hokkaido, Tohoku or other Japanese regions was supplied. Consequently, regional shares, regional production volumes and prefectural contributions are not assigned. At the national level, oral administration accounts for approximately 43.3% of the supplied 2026 route total, injectables 26.2%, nasal therapies 18.1%, and other routes 12.4%.

Top players in Japan Endometriosis Treatment Market

• ASKA Pharmaceutical Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Bayer AG
• AbbVie Inc.
• Pfizer Inc.
• Organon & Co.
• Astellas Pharma Inc.
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Chugai Pharmaceutical Co., Ltd.
• Nippon Shinyaku Co., Ltd.
• Kissei Pharmaceutical Co., Ltd.

Top Two Companies

• ASKA Pharmaceutical Co., Ltd. ASKA has strategically relevant positioning in Japanese women's health through its agreement covering relugolix. Takeda granted ASKA exclusive development and commercialization rights for relugolix for endometriosis in Japan. Relugolix is a once-daily oral GnRH receptor antagonist, aligning with movement toward convenient oral hormonal management. No reliable company-specific percentage revenue share was supplied; therefore, a numerical competitive share is not fabricated.
• Takeda Pharmaceutical Company Limited Takeda has an established role through the development history and licensing of relugolix. The compound was historically evaluated in more than 1,300 patients across multiple indications, while Takeda transferred exclusive Japanese endometriosis development and commercialization rights to ASKA. This provides Takeda with important R&D and intellectual-property positioning, although no verified Japan-specific company percentage share was provided.

Recent Developments in Japan Endometriosis Treatment Market

• 2026: PMDA updated the electronic clinical-data validation engine used with Validation Rule Version 6.0 in April 2026, strengthening standardized electronic drug-submission infrastructure.
• 2026: Japan implemented amendments to its conditional drug approval framework effective May 1, 2026, including provisions relating to post-approval quality, efficacy, and safety investigations.
• 2025: WHO reported that endometriosis affects approximately 10% of around 190 million reproductive-age women globally, reinforcing the scale of unmet therapeutic need.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 representing historical years. Mandatory supplied figures are retained without modification: USD 63.64 million in 2025, USD 71.91 million in 2026 and USD 191.19 million in 2034 for the drug-type dataset, representing a 12.95% CAGR. Segment percentages are calculated directly from supplied totals where required. Secondary contextual evidence is restricted to reputable regulatory, corporate and epidemiological sources, including PMDA, WHO, Takeda and peer-reviewed research. Geographic, surgery, distribution-channel, end-user and company-share figures absent from the supplied dataset are not fabricated.